[1]
|
NUCLEOTIDE SEQUENCE [GENOMIC RNA].
DOI=10.1038/313277a0; PubMed=2578615 [NCBI, ExPASy, EBI, Israel, Japan]
Ratner L.,
Haseltine W.A.,
Patarca R.,
Livak K.J.,
Starcich B.R.,
Josephs S.F.,
Doran E.R.,
Rafalski J.A.,
Whitehorn E.A.,
Baumeister K.,
Ivanoff L.,
Petteway S.R. Jr.,
Pearson M.L.,
Lautenberger J.A.,
Papas T.S.,
Ghrayeb J.,
Chang N.T.,
Gallo R.C.,
Wong-Staal F.;
"Complete nucleotide sequence of the AIDS virus, HTLV-III.";
Nature 313:277-284(1985).
|
[2]
|
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
STRAIN=Isolate PV22;
DOI=10.1038/313450a0; PubMed=2982104 [NCBI, ExPASy, EBI, Israel, Japan]
Muesing M.A.,
Smith D.H.,
Cabradilla C.D.,
Benton C.V.,
Lasky L.A.,
Capon D.J.;
"Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus.";
Nature 313:450-458(1985).
|
[3]
|
SEQUENCE REVISION.
Muesing M.A.;
Submitted (MAY-1992) to the EMBL/GenBank/DDBJ databases.
|
[4]
|
CHARACTERIZATION OF RNASE H.
PubMed=1722202 [NCBI, ExPASy, EBI, Israel, Japan]
DeStefano J.J.,
Buiser R.G.,
Mallaber L.M.,
Bambara R.A.,
Fay P.J.;
"Human immunodeficiency virus reverse transcriptase displays a partially processive 3' to 5' endonuclease activity.";
J. Biol. Chem. 266:24295-24301(1991).
|
[5]
|
PROTEOLYTIC PROCESSING OF POLYPROTEIN, AND MUTAGENESIS OF PHE-1039 AND LEU-1159.
DOI=10.1016/0014-5793(91)80583-O; PubMed=2044756 [NCBI, ExPASy, EBI, Israel, Japan]
Jupp R.A.,
Phylip L.H.,
Mills J.S.,
Le Grice S.F.J.,
Kay J.;
"Mutating P2 and P1 residues at cleavage junctions in the HIV-1 pol polyprotein. Effects on hydrolysis by HIV-1 proteinase.";
FEBS Lett. 283:180-184(1991).
|
[6]
|
MUTAGENESIS OF HIS-1138.
DOI=10.1016/0022-2836(91)90119-Q; PubMed=1714505 [NCBI, ExPASy, EBI, Israel, Japan]
Wohrl B.M.,
Volkmann S.,
Moelling K.;
"Mutations of a conserved residue within HIV-1 ribonuclease H affect its exo- and endonuclease activities.";
J. Mol. Biol. 220:801-818(1991).
|
[7]
|
ACTIVE SITES OF REVERSE TRANSCRIPTASE, AND MUTAGENESIS OF ASP-709; ASP-784 AND ASP-785.
DOI=10.1021/bi960364x; PubMed=8794733 [NCBI, ExPASy, EBI, Israel, Japan]
Kaushik N.,
Rege N.,
Yadav P.N.S.,
Sarafianos S.G.,
Modak M.J.,
Pandey V.N.;
"Biochemical analysis of catalytically crucial aspartate mutants of human immunodeficiency virus type 1 reverse transcriptase.";
Biochemistry 35:11536-11546(1996).
|
[8]
|
MUTAGENESIS OF GLU-823; PRO-824; PRO-825; PHE-826; LEU-827; TRP-828; MET-829; GLY-830; TYR-831; GLU-832 AND HIS-834.
DOI=10.1074/jbc.272.17.11157; PubMed=9111014 [NCBI, ExPASy, EBI, Israel, Japan]
Palaniappan C.,
Wisniewski M.,
Jacques P.S.,
Le Grice S.F.,
Fay P.J.,
Bambara R.A.;
"Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNase H function.";
J. Biol. Chem. 272:11157-11164(1997).
|
[9]
|
MUTAGENESIS OF PRO-651; PRO-654; LEU-673; SER-755; PRO-756; MET-783; ILE-856; GLY-861; LEU-863; TRP-865; LEU-878; ALA-898; LEU-902; LEU-909 AND GLU-1077.
DOI=10.1006/jmbi.1998.1624; PubMed=9533880 [NCBI, ExPASy, EBI, Israel, Japan]
Gao H.-Q.,
Boyer P.L.,
Arnold E.,
Hughes S.H.;
"Effects of mutations in the polymerase domain on the polymerase, RNase H and strand transfer activities of human immunodeficiency virus type 1 reverse transcriptase.";
J. Mol. Biol. 277:559-572(1998).
|
[10]
|
MUTAGENESIS OF TYR-782; MET-783; ASP-784 AND ASP-785.
DOI=10.1021/bi980549z; PubMed=9657675 [NCBI, ExPASy, EBI, Israel, Japan]
Harris D.,
Yadav P.N.S.,
Pandey V.N.;
"Loss of polymerase activity due to Tyr to Phe substitution in the YMDD motif of human immunodeficiency virus type-1 reverse transcriptase is compensated by Met to Val substitution within the same motif.";
Biochemistry 37:9630-9640(1998).
|
[11]
|
FUNCTION OF RNASE H.
PubMed=9658129 [NCBI, ExPASy, EBI, Israel, Japan]
Smith C.M.,
Leon O.,
Smith J.S.,
Roth M.J.;
"Sequence requirements for removal of tRNA by an isolated human immunodeficiency virus type 1 RNase H domain.";
J. Virol. 72:6805-6812(1998).
|
[12]
|
MUTAGENESIS OF LYS-664.
DOI=10.1042/0264-6021:3480077; PubMed=10794716 [NCBI, ExPASy, EBI, Israel, Japan]
Sluis-Cremer N.,
Arion D.,
Kaushik N.,
Lim H.,
Parniak M.A.;
"Mutational analysis of Lys65 of HIV-1 reverse transcriptase.";
Biochem. J. 348:77-82(2000).
|
[13]
|
CHARACTERIZATION OF RNASE H.
DOI=10.1073/pnas.210392297; PubMed=11035788 [NCBI, ExPASy, EBI, Israel, Japan]
Wisniewski M.,
Balakrishnan M.,
Palaniappan C.,
Fay P.J.,
Bambara R.A.;
"Unique progressive cleavage mechanism of HIV reverse transcriptase RNase H.";
Proc. Natl. Acad. Sci. U.S.A. 97:11978-11983(2000).
|
[14]
|
RIBOSOMAL FRAMESHIFT, PROTEOLYTIC PROCESSING OF POLYPROTEIN, AND MUTAGENESIS OF PHE-440 AND PHE-500.
PubMed=11172099 [NCBI, ExPASy, EBI, Israel, Japan]
Chen N.,
Morag A.,
Almog N.,
Blumenzweig I.,
Dreazin O.,
Kotler M.;
"Extended nucleocapsid protein is cleaved from the Gag-Pol precursor of human immunodeficiency virus type 1.";
J. Gen. Virol. 82:581-590(2001).
|
[15]
|
GAG/GAG-POL RATIO.
DOI=10.1128/JVI.75.4.1834-1841.2001; PubMed=11160682 [NCBI, ExPASy, EBI, Israel, Japan]
Shehu-Xhilaga M.,
Crowe S.M.,
Mak J.;
"Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity.";
J. Virol. 75:1834-1841(2001).
|
[16]
|
ACTIVE SITE ASP-525 OF PROTEASE.
PubMed=12924029 [NCBI, ExPASy, EBI, Israel, Japan]
Koval'skii D.B.,
Kanibolotskii D.S.,
Dubina V.N.,
Korneliuk A.I.;
"Conformational changes in HIV-1 proteinase: effect of protonation of the active center on conformation of HIV-1 proteinase in water.";
Ukr. Biokhim. Zh. 74:135-138(2002).
|
[17]
|
MUTAGENESIS OF TRP-752; ILE-766; LEU-786 AND VAL-788.
DOI=10.1021/bi026311z; PubMed=12501197 [NCBI, ExPASy, EBI, Israel, Japan]
Sharma B.,
Kaushik N.,
Singh K.,
Kumar S.,
Pandey V.N.;
"Substitution of conserved hydrophobic residues in motifs B and C of HIV-1 RT alters the geometry of its catalytic pocket.";
Biochemistry 41:15685-15697(2002).
|
[18]
|
MUTAGENESIS OF TYR-1100.
DOI=10.1074/jbc.M110254200; PubMed=11684697 [NCBI, ExPASy, EBI, Israel, Japan]
Arion D.,
Sluis-Cremer N.,
Min K.-L.,
Abram M.E.,
Fletcher R.S.,
Parniak M.A.;
"Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones.";
J. Biol. Chem. 277:1370-1374(2002).
|
[19]
|
DOMAIN TRYPTOPHAN REPEAT MOTIF, AND MUTAGENESIS OF TRP-997; TRP-1000; TRP-1001; TYR-1004; TRP-1005; TRP-1009 AND TRP-1013.
DOI=10.1016/S0022-2836(02)01433-X; PubMed=12559908 [NCBI, ExPASy, EBI, Israel, Japan]
Tachedjian G.,
Aronson H.-E.,
de los Santos M.,
Seehra J.,
McCoy J.M.,
Goff S.P.;
"Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization.";
J. Mol. Biol. 326:381-396(2003).
|
[20]
|
CHARACTERIZATION OF RNASE H.
DOI=10.1016/j.jmb.2004.09.081; PubMed=15533434 [NCBI, ExPASy, EBI, Israel, Japan]
Schultz S.J.,
Zhang M.,
Champoux J.J.;
"Recognition of internal cleavage sites by retroviral RNases H.";
J. Mol. Biol. 344:635-652(2004).
|
[21]
|
CHARACTERIZATION OF REVERSE TRANSCRIPTASE, AND MUTAGENESIS OF TRP-1000.
DOI=10.1002/prot.20480; PubMed=15852304 [NCBI, ExPASy, EBI, Israel, Japan]
Tachedjian G.,
Radzio J.,
Sluis-Cremer N.;
"Relationship between enzyme activity and dimeric structure of recombinant HIV-1 reverse transcriptase.";
Proteins 60:5-13(2005).
|
[22]
|
CHARACTERIZATION OF RNASE H.
DOI=10.1093/nar/gki779; PubMed=16141194 [NCBI, ExPASy, EBI, Israel, Japan]
Mulder B.A.,
Anaya S.,
Yu P.,
Lee K.W.,
Nguyen A.,
Murphy J.,
Willson R.,
Briggs J.M.,
Gao X.,
Hardin S.H.;
"Nucleotide modification at the gamma-phosphate leads to the improved fidelity of HIV-1 reverse transcriptase.";
Nucleic Acids Res. 33:4865-4873(2005).
|
[23]
|
MUTAGENESIS OF ALA-1036; GLU-1037; THR-1038; PHE-1039; TYR-1040 AND VAL-1041.
DOI=10.1128/JVI.79.18.11952-11961.2005; PubMed=16140771 [NCBI, ExPASy, EBI, Israel, Japan]
Abram M.E.,
Parniak M.A.;
"Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain.";
J. Virol. 79:11952-11961(2005).
|
[24]
|
REVIEW.
PubMed=8791726 [NCBI, ExPASy, EBI, Israel, Japan]
Vogt V.M.;
"Proteolytic processing and particle maturation.";
Curr. Top. Microbiol. Immunol. 214:95-131(1996).
|
[25]
|
REVIEW.
DOI=10.1006/jmbi.1998.2354; PubMed=9878383 [NCBI, ExPASy, EBI, Israel, Japan]
Turner B.G.,
Summers M.F.;
"Structural biology of HIV.";
J. Mol. Biol. 285:1-32(1999).
|
[26]
|
REVIEW.
DOI=10.1146/annurev.genet.35.102401.090551; PubMed=11700285 [NCBI, ExPASy, EBI, Israel, Japan]
Negroni M.,
Buc H.;
"Mechanisms of retroviral recombination.";
Annu. Rev. Genet. 35:275-302(2001).
|
[27]
|
REVIEW.
PubMed=11983066 [NCBI, ExPASy, EBI, Israel, Japan]
Dunn B.M.,
Goodenow M.M.,
Gustchina A.,
Wlodawer A.;
"Retroviral proteases.";
Genome Biol. 3:REVIEWS3006.1-REVIEWS3006.7(2002).
|
[28]
|
REVIEW.
DOI=10.1016/S0005-2736(03)00163-9; PubMed=12873766 [NCBI, ExPASy, EBI, Israel, Japan]
Scarlata S.,
Carter C.;
"Role of HIV-1 Gag domains in viral assembly.";
Biochim. Biophys. Acta 1614:62-72(2003).
|
[29]
|
3D-STRUCTURE MODELING OF PROTEASE DOMAIN.
PubMed=2537531 [NCBI, ExPASy, EBI, Israel, Japan]
Weber I.T.,
Miller M.,
Jaskolski M.,
Leis J.,
Skalka A.M.,
Wlodawer A.;
"Molecular modeling of the HIV-1 protease and its substrate binding site.";
Science 243:928-931(1989).
|
[30]
|
X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 600-1159.
DOI=10.1016/0003-9861(89)90493-1; PubMed=2476069 [NCBI, ExPASy, EBI, Israel, Japan]
Mizrahi V.,
Lazarus G.M.,
Miles L.M.,
Meyers C.A.,
Debouck C.;
"Recombinant HIV-1 reverse transcriptase: purification, primary structure, and polymerase/ribonuclease H activities.";
Arch. Biochem. Biophys. 273:347-358(1989).
|
[31]
|
X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 501-599 IN COMPLEX WITH A C2 SYMMETRIC INHIBITOR.
PubMed=2200122 [NCBI, ExPASy, EBI, Israel, Japan]
Erickson J.,
Neidhart D.J.,
Vandrie J.,
Kempf D.J.,
Wang X.C.,
Norbeck D.W.,
Plattner J.J.,
Rittenhouse J.W.,
Turon M.,
Wideburg N.E.,
Kohlbrenner W.E.,
Simmer R.,
Helfrich R.,
Paul D.A.,
Knigge M.;
"Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.";
Science 249:527-533(1990).
|
[32]
|
X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1026-1161.
PubMed=1707186 [NCBI, ExPASy, EBI, Israel, Japan]
Davies J.F. II,
Hostomska Z.,
Hostomsky Z.,
Jordan S.R.,
Matthews D.A.;
"Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase.";
Science 252:88-95(1991).
|
[33]
|
X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1026-1159.
PubMed=1718968 [NCBI, ExPASy, EBI, Israel, Japan]
Evans D.B.,
Brawn K.,
Deibel M.R. Jr.,
Tarpley W.G.,
Sharma S.K.;
"A recombinant ribonuclease H domain of HIV-1 reverse transcriptase that is enzymatically active.";
J. Biol. Chem. 266:20583-20585(1991).
|
[34]
|
X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1026-1161.
PubMed=1713588 [NCBI, ExPASy, EBI, Israel, Japan]
Hostomska Z.,
Matthews D.A.,
Davies J.F. II,
Nodes B.R.,
Hostomsky Z.;
"Proteolytic release and crystallization of the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase.";
J. Biol. Chem. 266:14697-14702(1991).
|
[35]
|
X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS) OF 600-1155 IN COMPLEX WITH AN INHIBITOR.
PubMed=1377403 [NCBI, ExPASy, EBI, Israel, Japan]
Kohlstaedt L.A.,
Wang J.,
Friedman J.M.,
Rice P.A.,
Steitz T.A.;
"Crystal structure at 3.5-A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.";
Science 256:1783-1790(1992).
|
[36]
|
X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 600-1157.
DOI=10.1038/357085a0; PubMed=1374166 [NCBI, ExPASy, EBI, Israel, Japan]
Arnold E.,
Jacobo-Molina A.,
Nanni R.G.,
Williams R.L.,
Lu X.,
Ding J.,
Clark A.D. Jr.,
Zhang A.,
Ferris A.L.,
Clark P.,
Hizi A.,
Hughes S.H.;
"Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations.";
Nature 357:85-89(1992).
|
[37]
|
X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 501-599.
DOI=10.1021/jm00073a010; PubMed=8230097 [NCBI, ExPASy, EBI, Israel, Japan]
Wonacott A.,
Cooke R.,
Hayes F.R.,
Hann M.M.,
Jhoti H.,
McMeekin P.,
Mistry A.,
Murray-Rust P.,
Singh O.M.,
Weir M.P.;
"A series of penicillin-derived C2-symmetric inhibitors of HIV-1 proteinase: structural and modeling studies.";
J. Med. Chem. 36:3113-3119(1993).
|
[38]
|
X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 501-599 IN COMPLEX WITH A NOVEL GAMMA-TURN MIMETIC INHIBITOR.
DOI=10.1021/jm00068a008; PubMed=8360876 [NCBI, ExPASy, EBI, Israel, Japan]
Newlander K.A.,
Callahan J.F.,
Moore M.L.,
Tomaszek T.A. Jr.,
Huffman W.F.;
"A novel constrained reduced-amide inhibitor of HIV-1 protease derived from the sequential incorporation of gamma-turn mimetics into a model substrate.";
J. Med. Chem. 36:2321-2331(1993).
|
[39]
|
X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 600-1155.
PubMed=7687065 [NCBI, ExPASy, EBI, Israel, Japan]
Jacobo-Molina A.,
Ding J.,
Nanni R.G.,
Clark A.D. Jr.,
Lu X.,
Tantillo C.,
Williams R.L.,
Kamer G.,
Ferris A.L.,
Clark P.,
Hizi A.,
Hughes S.H.,
Arnold E.;
"Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0-A resolution shows bent DNA.";
Proc. Natl. Acad. Sci. U.S.A. 90:6320-6324(1993).
|
[40]
|
X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 600-1159.
PubMed=7513427 [NCBI, ExPASy, EBI, Israel, Japan]
Smerdon S.J.,
Jager J.,
Wang J.,
Kohlstaedt L.A.,
Chirino A.J.,
Friedman J.M.,
Rice P.A.,
Steitz T.A.;
"Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1.";
Proc. Natl. Acad. Sci. U.S.A. 91:3911-3915(1994).
|
[41]
|
X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 501-599 IN COMPLEX WITH A NOVEL PSEUDOSYMMETRIC INHIBITOR.
DOI=10.1016/S0969-2126(01)00169-1; PubMed=7613867 [NCBI, ExPASy, EBI, Israel, Japan]
Priestle J.P.,
Fassler A.,
Rosel J.,
Tintelnot-Blomley M.,
Strop P.,
Gruetter M.G.;
"Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor.";
Structure 3:381-389(1995).
|
[42]
|
X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 600-1155 IN COMPLEX WITH A NONNUCLEOSIDE INHIBITOR.
DOI=10.1038/nsb0595-407; PubMed=7545077 [NCBI, ExPASy, EBI, Israel, Japan]
Ding J.,
Das K.,
Moereels H.,
Koymans L.,
Andries K.,
Janssen P.A.,
Hughes S.H.,
Arnold E.;
"Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors.";
Nat. Struct. Biol. 2:407-415(1995).
|
[43]
|
X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 600-1157 IN COMPLEX WITH A NON-NUCLEOSIDE INHIBITOR.
DOI=10.1016/S0969-2126(01)00168-X; PubMed=7542140 [NCBI, ExPASy, EBI, Israel, Japan]
Ding J.,
Das K.,
Tantillo C.,
Zhang W.,
Clark A.D. Jr.,
Jessen S.,
Lu X.,
Hsiou Y.,
Jacobo-Molina A.,
Andries K.,
Et A.L.;
"Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8-A resolution.";
Structure 3:365-379(1995).
|
[44]
|
X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 600-1159.
PubMed=7532306 [NCBI, ExPASy, EBI, Israel, Japan]
Rodgers D.W.,
Gamblin S.J.,
Harris B.A.,
Ray S.,
Culp J.S.,
Hellmig B.,
Woolf D.J.,
Debouck C.,
Harrison S.C.;
"The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1.";
Proc. Natl. Acad. Sci. U.S.A. 92:1222-1226(1995).
|
[45]
|
STRUCTURE BY NMR OF 1379-1429.
DOI=10.1038/nsb0995-807; PubMed=7552753 [NCBI, ExPASy, EBI, Israel, Japan]
Eijkelenboom A.P.A.M.,
Lutzke R.A.,
Boelens R.,
Plasterk R.H.A.,
Kaptein R.,
Hard K.;
"The DNA-binding domain of HIV-1 integrase has an SH3-like fold.";
Nat. Struct. Biol. 2:807-810(1995).
|
[46]
|
X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 501-599 IN COMPLEX WITH THE PEPTIDIC INHIBITOR U-89360E.
DOI=10.1021/bi00004a007; PubMed=7827064 [NCBI, ExPASy, EBI, Israel, Japan]
Lin Y.Z.,
Lin X.L.,
Hong L.,
Foundling S.I.,
Heinrikson R.L.,
Thaisrivongs S.,
Leelamanit W.,
Raterman D.,
Shah M.,
Dunn B.M.,
Tang J.;
"Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance.";
Biochemistry 34:1143-1152(1995).
|
[47]
|
X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 600-1155.
DOI=10.1016/S0969-2126(96)00091-3; PubMed=8805568 [NCBI, ExPASy, EBI, Israel, Japan]
Hsiou Y.,
Ding J.,
Das K.,
Clark A.D. Jr.,
Hughes S.H.,
Arnold E.;
"Structure of unliganded HIV-1 reverse transcriptase at 2.7-A resolution: implications of conformational changes for polymerization and inhibition mechanisms.";
Structure 4:853-860(1996).
|
[48]
|
X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 501-599 IN COMPLEX WITH A SULFAMIDE AND A UREA DERIVATIVE.
DOI=10.1021/jm960588d; PubMed=9083478 [NCBI, ExPASy, EBI, Israel, Japan]
Backbro K.,
Lowgren S.,
Osterlund K.,
Atepo J.,
Unge T.,
Hulten J.,
Bonham N.M.,
Schaal W.,
Karlen A.,
Hallberg A.;
"Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.";
J. Med. Chem. 40:898-902(1997).
|
[49]
|
X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 502-599 IN COMPLEX WITH A CYCLIC UREA INHIBITOR.
DOI=10.1021/bi962234u; PubMed=9048541 [NCBI, ExPASy, EBI, Israel, Japan]
Ala P.J.,
Huston E.E.,
Klabe R.M.,
McCabe D.D.,
Duke J.L.,
Rizzo C.J.,
Korant B.D.,
DeLoskey R.J.,
Lam P.Y.S.,
Hodge C.N.,
Chang C.-H.;
"Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors.";
Biochemistry 36:1573-1580(1997).
|
[50]
|
X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 501-599 IN COMPLEX WITH THE PEPTIDIC INHIBITOR U-89360E.
DOI=10.1016/S0014-5793(97)01477-4; PubMed=9450540 [NCBI, ExPASy, EBI, Israel, Japan]
Hong L.,
Zhang X.-J.,
Foundling S.I.,
Hartsuck J.A.,
Tang J.;
"Structure of a G48H mutant of HIV-1 protease explains how glycine-48 replacements produce mutants resistant to inhibitor drugs.";
FEBS Lett. 420:11-16(1997).
|
[51]
|
X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 501-599.
DOI=10.1021/jm970195u; PubMed=9258349 [NCBI, ExPASy, EBI, Israel, Japan]
Smith A.B. III,
Hirschmann R.,
Pasternak A.,
Yao W.,
Sprengeler P.A.,
Holloway M.K.,
Kuo L.C.,
Chen Z.,
Darke P.L.,
Schleif W.A.;
"An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.";
J. Med. Chem. 40:2440-2444(1997).
|
[52]
|
X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 501-599 IN COMPLEX WITH A PEPTIDIC INHIBITOR.
PubMed=9521105 [NCBI, ExPASy, EBI, Israel, Japan]
Hong L.,
Hartsuck J.A.,
Foundling S.I.,
Ermolieff J.,
Tang J.;
"Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant.";
Protein Sci. 7:300-305(1998).
|
[53]
|
X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 588-1027.
DOI=10.1126/science.282.5394.1669; PubMed=9831551 [NCBI, ExPASy, EBI, Israel, Japan]
Huang H.,
Chopra R.,
Verdine G.L.,
Harrison S.C.;
"Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.";
Science 282:1669-1675(1998).
|
[54]
|
X-RAY CRYSTALLOGRAPHY (4.75 ANGSTROMS) OF 600-1153 IN COMPLEX WITH AN RNA PSEUDOKNOT INHIBITOR.
DOI=10.1093/emboj/17.15.4535; PubMed=9687519 [NCBI, ExPASy, EBI, Israel, Japan]
Jaeger J.,
Restle T.,
Steitz T.A.;
"The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor.";
EMBO J. 17:4535-4542(1998).
|
[55]
|
X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 600-1155 IN COMPLEX WITH A NON-NUCLEOSIDE INHIBITOR.
DOI=10.1006/jmbi.1998.2171; PubMed=9813120 [NCBI, ExPASy, EBI, Israel, Japan]
Hsiou Y.,
Das K.,
Ding J.,
Clark A.D. Jr.,
Kleim J.P.,
Rosner M.,
Winkler I.,
Riess G.,
Hughes S.H.,
Arnold E.;
"Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.";
J. Mol. Biol. 284:313-323(1998).
|
[56]
|
X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS) OF 600-1157.
DOI=10.1073/pnas.96.18.10027; PubMed=10468556 [NCBI, ExPASy, EBI, Israel, Japan]
Sarafianos S.G.,
Das K.,
Clark A.D. Jr.,
Ding J.,
Boyer P.L.,
Hughes S.H.,
Arnold E.;
"Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids.";
Proc. Natl. Acad. Sci. U.S.A. 96:10027-10032(1999).
|
[57]
|
X-RAY CRYSTALLOGRAPHY (2.73 ANGSTROMS) OF 600-1156.
DOI=10.1021/jm990572y; PubMed=10650066 [NCBI, ExPASy, EBI, Israel, Japan]
Hogberg M.,
Sahlberg C.,
Engelhardt P.,
Noreen R.,
Kangasmetsa J.,
Johansson N.G.,
Oberg B.,
Vrang L.,
Zhang H.,
Sahlberg B.L.,
Unge T.,
Lovgren S.,
Fridborg K.,
Backbro K.;
"Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.";
J. Med. Chem. 43:304-304(2000).
|
[58]
|
X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 600-1152 IN COMPLEX WITH AN OLIGONUCLEOTIDE, AND ACTIVE SITES OF RNASE H.
DOI=10.1093/emboj/20.6.1449; PubMed=11250910 [NCBI, ExPASy, EBI, Israel, Japan]
Sarafianos S.G.,
Das K.,
Tantillo C.,
Clark A.D. Jr.,
Ding J.,
Whitcomb J.M.,
Boyer P.L.,
Hughes S.H.,
Arnold E.;
"Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA.";
EMBO J. 20:1449-1461(2001).
|
[59]
|
X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 600-1159.
DOI=10.1006/jmbi.2001.4648; PubMed=11371163 [NCBI, ExPASy, EBI, Israel, Japan]
Hsiou Y.,
Ding J.,
Das K.,
Clark A.D. Jr.,
Boyer P.L.,
Lewi P.,
Janssen P.A.,
Kleim J.P.,
Rosner M.,
Hughes S.H.,
Arnold E.;
"The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.";
J. Mol. Biol. 309:437-445(2001).
|
[60]
|
X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 600-1157.
DOI=10.1093/emboj/cdf637; PubMed=12456667 [NCBI, ExPASy, EBI, Israel, Japan]
Sarafianos S.G.,
Clark A.D. Jr.,
Das K.,
Tuske S.,
Birktoft J.J.,
Ilankumaran P.,
Ramesha A.R.,
Sayer J.M.,
Jerina D.M.,
Boyer P.L.,
Hughes S.H.,
Arnold E.;
"Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA.";
EMBO J. 21:6614-6624(2002).
|
[61]
|
X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 600-1159 IN COMPLEX WITH EFIVARENZ.
PubMed=11895437 [NCBI, ExPASy, EBI, Israel, Japan]
Lindberg J.,
Sigurdsson S.,
Lowgren S.,
Andersson H.O.,
Sahlberg C.,
Noreen R.,
Fridborg K.,
Zhang H.,
Unge T.;
"Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant.";
Eur. J. Biochem. 269:1670-1677(2002).
|
[62]
|
X-RAY CRYSTALLOGRAPHY (1.81 ANGSTROMS) OF 501-599.
DOI=10.1046/j.1432-1033.2003.03533.x; PubMed=12694187 [NCBI, ExPASy, EBI, Israel, Japan]
Andersson H.O.,
Fridborg K.,
Lowgren S.,
Alterman M.,
Muhlman A.,
Bjorsne M.,
Garg N.,
Kvarnstrom I.,
Schaal W.,
Classon B.,
Karlen A.,
Danielsson U.H.,
Ahlsen G.,
Nillroth U.,
Vrang L.,
Oberg B.,
Samuelsson B.,
Hallberg A.,
Unge T.;
"Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors.";
Eur. J. Biochem. 270:1746-1758(2003).
|
[63]
|
X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 501-599 IN COMPLEX WITH MONOPYRROLINONE-BASED INHIBITORS LDC271 AND LGZ479.
DOI=10.1021/jm0204587; PubMed=12723947 [NCBI, ExPASy, EBI, Israel, Japan]
Smith A.B. III,
Cantin L.D.,
Pasternak A.,
Guise-Zawacki L.,
Yao W.,
Charnley A.K.,
Barbosa J.,
Sprengeler P.A.,
Hirschmann R.,
Munshi S.,
Olsen D.B.,
Schleif W.A.,
Kuo L.C.;
"Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.";
J. Med. Chem. 46:1831-1844(2003).
|
[64]
|
X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 501-599.
DOI=10.1111/j.1432-1033.2004.04431.x; PubMed=15560801 [NCBI, ExPASy, EBI, Israel, Japan]
Lindberg J.,
Pyring D.,
Lowgren S.,
Rosenquist A.,
Zuccarello G.,
Kvarnstrom I.,
Zhang H.,
Vrang L.,
Classon B.,
Hallberg A.,
Samuelsson B.,
Unge T.;
"Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.";
Eur. J. Biochem. 271:4594-4602(2004).
|
[65]
|
X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 600-1157.
DOI=10.1128/JVI.78.7.3387-3397.2004; PubMed=15016861 [NCBI, ExPASy, EBI, Israel, Japan]
Peletskaya E.N.,
Kogon A.A.,
Tuske S.,
Arnold E.,
Hughes S.H.;
"Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA.";
J. Virol. 78:3387-3397(2004).
|
[66]
|
X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 600-1157 IN COMPLEX WITH DNA BOUND TO TENOFOVIR.
DOI=10.1038/nsmb760; PubMed=15107837 [NCBI, ExPASy, EBI, Israel, Japan]
Tuske S.,
Sarafianos S.G.,
Clark A.D. Jr.,
Ding J.,
Naeger L.K.,
White K.L.,
Miller M.D.,
Gibbs C.S.,
Boyer P.L.,
Clark P.,
Wang G.,
Gaffney B.L.,
Jones R.A.,
Jerina D.M.,
Hughes S.H.,
Arnold E.;
"Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir.";
Nat. Struct. Mol. Biol. 11:469-474(2004).
|
[67]
|
X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) OF 501-599 IN COMPLEX WITH ARYLSULFONAMIDE AZACYCLIC UREA INHIBITORS.
DOI=10.1016/j.bmcl.2004.05.036; PubMed=15225729 [NCBI, ExPASy, EBI, Israel, Japan]
Huang P.P.,
Randolph J.T.,
Klein L.L.,
Vasavanonda S.,
Dekhtyar T.,
Stoll V.S.,
Kempf D.J.;
"Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.";
Bioorg. Med. Chem. Lett. 14:4075-4078(2004).
|
[68]
|
X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 501-599 IN COMPLEX WITH OXIMINOARYLSULFONAMIDE INHIBITOR.
DOI=10.1016/j.bmcl.2005.03.008; PubMed=15837308 [NCBI, ExPASy, EBI, Israel, Japan]
Yeung C.M.,
Klein L.L.,
Flentge C.A.,
Randolph J.T.,
Zhao C.,
Sun M.,
Dekhtyar T.,
Stoll V.S.,
Kempf D.J.;
"Oximinoarylsulfonamides as potent HIV protease inhibitors.";
Bioorg. Med. Chem. Lett. 15:2275-2278(2005).
|
|